Anti-EGFR antibodies and antibody drug conjugates
The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
1. An anti-human epidermal growth factor receptor (anti-hEGFR) antibody comprising
a heavy chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 18, a heavy chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 17, and a heavy chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 16; and
a light chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 25, a light chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 24, and a light chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 23,
wherein the antibody is an IgG isotype.
2. The antibody of claim 1 , wherein the anti-hEGFR antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 72, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 73.
3. An antibody drug conjugate (ADC) comprising the anti-hEGFR antibody of claim 1 , conjugated to at least one drug.
4. A pharmaceutical composition comprising the ADC of claim 3 , and a pharmaceutically acceptable carrier.
5. An anti-human epidermal growth factor receptor (anti-hEGFR) antibody comprising
a heavy chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 19, a heavy chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 11, and a heavy chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 10; and
a light chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 28, a light chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 27, and a light chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 26,
wherein the antibody is an IgG isotype.
6. The antibody of claim 5 , wherein the anti-hEGFR antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 74, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 75.
7. An antibody drug conjugate (ADC) comprising the anti-hEGFR antibody of claim 5 , conjugated to at least one drug.
8. A pharmaceutical composition comprising the ADC of claim 7 , and a pharmaceutically acceptable carrier.
9. An anti-human epidermal growth factor receptor (anti-hEGFR) antibody comprising
a heavy chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 19, a heavy chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 17, and a heavy chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 16; and
a light chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 8, a light chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 7, and a light chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 6,
wherein the antibody is an IgG isotype.
10. The anti-hEGFR antibody of claim 9 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 64, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 65.
11. An antibody drug conjugate (ADC) comprising the anti-hEGFR antibody of claim 9 , conjugated to at least one drug.
12. A pharmaceutical composition comprising the ADC of claim 11 , and a pharmaceutically acceptable carrier.
13. The ADC of claim 3 , wherein the at least one drug is selected from the group consisting of a dolastatin, a maytansinoid, and a plant alkaloid.
14. The ADC of claim 3 , wherein the at least one drug is an auristatin.
15. The ADC of claim 14 , wherein the auristatin is monomethylauristatin E (MMAE) or monomethylauristatin F (MMAF).
16. The ADC of claim 7 , wherein the at least one drug is selected from the group consisting of a dolastatin, a maytansinoid, and a plant alkaloid.
17. The ADC of claim 7 , wherein the at least one drug is an auristatin.
18. The ADC of claim 17 , wherein the auristatin is MMAE or MMAF.
19. The ADC of claim 18 , wherein the at least one drug is selected from the group consisting of a dolastatin, a maytansinoid, and a plant alkaloid.
20. The ADC of claim 18 , wherein the at least one drug is an auristatin.
21. The ADC of claim 20 , wherein the auristatin is MMAE or MMAF.